Clinical significance of serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis.

Kanako KatayamaMasaki HiroseToru AraiKazuyoshi HatsudaKazunobu TachibanaReiko SugawaraChikatoshi SugimotoTakahiko KasaiMasanori AkiraYoshikazu Inoue

Published in: Orphanet journal of rare diseases (2020)

We demonstrated the percentage of elevated-GMAb sarcoidosis and HP patients who presented with several features suggestive of aPAP. Elevated-GMAb sarcoidosis and HP patients without definitive aPAP diagnosis may have subclinical or early-stage aPAP and may not necessarily indicate false positives. Upon diagnosis of sarcoidosis or HP, measurement of GMAb may be useful in detecting possible comorbidity of subclinical or early-onset aPAP.

Keyphrases

early onset
early stage
end stage renal disease
late onset
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
adipose tissue
systemic lupus erythematosus
prognostic factors
squamous cell carcinoma
radiation therapy
peripheral blood
patient reported outcomes